Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling-Reference-Cited by-同舟云学术

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Published:2011-07-06 Issue:90 Volume:3 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Chmielecki Juliann¹,Foo Jasmine²,Oxnard Geoffrey R.³,Hutchinson Katherine⁴,Ohashi Kadoaki⁴,Somwar Romel⁵,Wang Lu⁶,Amato Katherine R.⁴,Arcila Maria⁶,Sos Martin L.⁷,Socci Nicholas D.⁸,Viale Agnes⁹,de Stanchina Elisa¹⁰,Ginsberg Michelle S.¹¹,Thomas Roman K.⁷¹²¹³,Kris Mark G.³,Inoue Akira¹⁴,Ladanyi Marc⁶¹⁵,Miller Vincent A.³,Michor Franziska²,Pao William⁴

Affiliation:

1. Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA.

2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA.

3. Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

4. Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.

5. Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

6. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

7. Max Planck Institute for Neurological Research with Klaus Joachim Zülch Laboratories of the Max Planck Society and the Medical Faculty, 50931 Cologne, Germany.

8. Bioinformatics Core, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

9. Genomics Core Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

10. Anti-Tumor Assessment Core Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

11. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

12. Department I of Internal Medicine and Center of Integrated Oncology Köln-Bonn, University of Cologne, 50924 Cologne, Germany.

13. Chemical Genomics Center of the Max Planck Society, 44227 Dortmund, Germany.

14. Department of Respiratory Medicine, Tohoku University Hospital, 1-1 Seiryomachi, Aobaku, Sendai 3831, Japan.

15. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Abstract

Predictive models of EGFR-mutant tumor behavior point to alternative drug dosing strategies to prevent and treat acquired resistance.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference55 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

3. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

4. Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

5. Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib

Cited by 467 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DataXflow: Synergizing data-driven modeling with best parameter fit and optimal control – An efficient data analysis for cancer research;Computational and Structural Biotechnology Journal;2024-12

2. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?;CLIN LUNG CANCER;2024

3. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?;Clinical Lung Cancer;2024-09

4. Characterization of the in vitro metabolic profile of nazartinib in HLMs using UPLC-MS/MS method: In silico metabolic lability and DEREK structural alerts screening using StarDrop software;Heliyon;2024-07

5. Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice;Journal of Pharmacokinetics and Pharmacodynamics;2024-06-21